JP2013506626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506626A5 JP2013506626A5 JP2012531285A JP2012531285A JP2013506626A5 JP 2013506626 A5 JP2013506626 A5 JP 2013506626A5 JP 2012531285 A JP2012531285 A JP 2012531285A JP 2012531285 A JP2012531285 A JP 2012531285A JP 2013506626 A5 JP2013506626 A5 JP 2013506626A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- proteasome inhibitor
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 19
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 8
- 239000003207 proteasome inhibitor Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24771409P | 2009-10-01 | 2009-10-01 | |
| US61/247,714 | 2009-10-01 | ||
| PCT/EP2010/005994 WO2011038924A2 (en) | 2009-10-01 | 2010-10-01 | Treatment of disease with proteasome inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013506626A JP2013506626A (ja) | 2013-02-28 |
| JP2013506626A5 true JP2013506626A5 (https=) | 2013-11-21 |
Family
ID=43629456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012531285A Pending JP2013506626A (ja) | 2009-10-01 | 2010-10-01 | 癌治療用のプロテアソーム阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110189204A1 (https=) |
| EP (1) | EP2519231B1 (https=) |
| JP (1) | JP2013506626A (https=) |
| AU (2) | AU2010300259A1 (https=) |
| CA (1) | CA2776327A1 (https=) |
| CY (1) | CY1118925T1 (https=) |
| DK (1) | DK2519231T3 (https=) |
| ES (1) | ES2624644T3 (https=) |
| HR (1) | HRP20170702T1 (https=) |
| HU (1) | HUE032571T2 (https=) |
| LT (1) | LT2519231T (https=) |
| ME (1) | ME02725B (https=) |
| PL (1) | PL2519231T3 (https=) |
| PT (1) | PT2519231T (https=) |
| RS (1) | RS55931B1 (https=) |
| SI (1) | SI2519231T1 (https=) |
| SM (1) | SMT201700231T1 (https=) |
| WO (1) | WO2011038924A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039328B (zh) * | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| CA2966288A1 (en) * | 2014-10-30 | 2016-05-06 | Big Dna Ltd | Combination therapy |
| WO2017070328A1 (en) * | 2015-10-20 | 2017-04-27 | The Cleveland Clinic Foundation | STIMULATION OF 11β-HSD2 EXPRESSION TO IMPROVE HORMONAL THERAPY OF STEROID-DEPENDENT DISEASE |
| US11947330B2 (en) * | 2019-03-06 | 2024-04-02 | The Boeing Company | Tool orientation systems and methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4499802A (en) * | 1982-09-29 | 1985-02-19 | Container Graphics Corporation | Rotary cutting die with scrap ejection |
| US4537773A (en) | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| US5081110A (en) * | 1986-03-27 | 1992-01-14 | Sloan-Kettering Institute For Cancer Research | Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CN1339970A (zh) * | 1999-02-10 | 2002-03-13 | 鹤尾隆 | 抗癌药物增强剂 |
| JP4162491B2 (ja) * | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
| KR20070107707A (ko) | 2005-01-21 | 2007-11-07 | 아스텍스 테라퓨틱스 리미티드 | 피라졸 키나제 억제제와 추가 항종양제의 조합물 |
| MX2007008781A (es) | 2005-01-21 | 2007-09-11 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| US20060193844A1 (en) * | 2005-02-28 | 2006-08-31 | Proteolix, Inc. | Methods for enzyme inhibition |
| EP1876893B1 (en) * | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2008086005A1 (en) * | 2007-01-09 | 2008-07-17 | University Of South Florida | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| MX2010002179A (es) * | 2007-08-24 | 2010-04-27 | Stichting Het Nl Kanker I | Composicion para el tratamiento de enfermedades neoplasicas. |
-
2010
- 2010-10-01 HU HUE10807320A patent/HUE032571T2/en unknown
- 2010-10-01 AU AU2010300259A patent/AU2010300259A1/en not_active Abandoned
- 2010-10-01 SI SI201031448A patent/SI2519231T1/sl unknown
- 2010-10-01 DK DK10807320.6T patent/DK2519231T3/en active
- 2010-10-01 HR HRP20170702TT patent/HRP20170702T1/hr unknown
- 2010-10-01 LT LTEP10807320.6T patent/LT2519231T/lt unknown
- 2010-10-01 PL PL10807320T patent/PL2519231T3/pl unknown
- 2010-10-01 RS RS20170474A patent/RS55931B1/sr unknown
- 2010-10-01 JP JP2012531285A patent/JP2013506626A/ja active Pending
- 2010-10-01 SM SM20170231T patent/SMT201700231T1/it unknown
- 2010-10-01 US US12/896,289 patent/US20110189204A1/en not_active Abandoned
- 2010-10-01 ME MEP-2017-106A patent/ME02725B/me unknown
- 2010-10-01 ES ES10807320.6T patent/ES2624644T3/es active Active
- 2010-10-01 EP EP10807320.6A patent/EP2519231B1/en not_active Revoked
- 2010-10-01 CA CA2776327A patent/CA2776327A1/en not_active Abandoned
- 2010-10-01 WO PCT/EP2010/005994 patent/WO2011038924A2/en not_active Ceased
- 2010-10-01 PT PT108073206T patent/PT2519231T/pt unknown
-
2016
- 2016-12-22 AU AU2016277700A patent/AU2016277700A1/en not_active Abandoned
-
2017
- 2017-06-01 CY CY20171100580T patent/CY1118925T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630790A (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| JP2016528162A5 (https=) | ||
| JP2017505321A5 (https=) | ||
| JP2014532704A5 (https=) | ||
| JP2012522837A5 (https=) | ||
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| RU2014130874A (ru) | Схема лечения рака молочной железы с использованием нератиниба | |
| JP2013506626A5 (https=) | ||
| JP2019526559A5 (https=) | ||
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| CN101991579A (zh) | 熊果酸作为抗结肠肿瘤药物的应用 | |
| HRP20170702T1 (hr) | Inhibitori proteazoma za liječenje karcinoma | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JPWO2019196764A5 (https=) | ||
| RU2010140888A (ru) | Улучшенные противораковые терапии | |
| Choi et al. | A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma | |
| Park et al. | Cutaneous metastatic undifferentiated pleomorphic sarcoma from a mediastinal sarcoma | |
| Xiao et al. | A clinical study on juheli (recombinant human interleukin-11) in the second prevention of chemotherapy induced thrombocytopenia | |
| RU2013149175A (ru) | Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы | |
| Jun et al. | Injection-site reaction following 5-azacitidine injection | |
| CN108042540B (zh) | 五氟利多在制备治疗食管癌药物中的应用 | |
| Glaspy et al. | 489 Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies | |
| Cheung et al. | IDDF2018-ABS-0153 Super-enhancer-associated master transcriptional circuitry in nafld-hcc development |